Pharming Group N.V. (PHAR)
NASDAQ: PHAR · Real-Time Price · USD
8.86
-0.09 (-1.01%)
Feb 21, 2025, 4:00 PM EST - Market closed
Pharming Group Revenue
Pharming Group had revenue of $74.85M in the quarter ending September 30, 2024, with 12.22% growth. This brings the company's revenue in the last twelve months to $285.75M, up 30.64% year-over-year. In the year 2023, Pharming Group had annual revenue of $245.32M with 19.30% growth.
Revenue (ttm)
$285.75M
Revenue Growth
+30.64%
P/S Ratio
2.17
Revenue / Employee
$748,024
Employees
382
Market Cap
620.37M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 245.32M | 39.69M | 19.30% |
| Dec 31, 2022 | 205.62M | 6.75M | 3.39% |
| Dec 31, 2021 | 198.87M | -13.30M | -6.27% |
| Dec 31, 2020 | 212.17M | 22.79M | 12.03% |
| Jan 1, 2020 | 189.39M | 54.26M | 40.15% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
PHAR News
- 15 days ago - Pharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of Abliva AB (publ) and extends the acceptance period - GlobeNewsWire
- 4 weeks ago - Pharming Group to convene Extraordinary General Meeting of Shareholders - GlobeNewsWire
- 4 weeks ago - Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer - GlobeNewsWire
- 2 months ago - Pharming announces public cash offer to the shareholders of Abliva AB - GlobeNewsWire
- 2 months ago - European Biotech Pharming Group Touts Positive Data From Pivotal Pediatric Study Of FDA-Approved Immune System Disorder Drug - Benzinga
- 3 months ago - Pharming Group to participate in November investor conference - GlobeNewsWire
- 4 months ago - Pharming Group N.V. (PHAR) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Pharming Group to report third quarter 2024 financial results on October 24 - GlobeNewsWire